Study: NCT03099174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xentuzumab
Description: Once weekly administrated through one hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Treatment/28-day cycle p.o. Q12H on Days 1-28 (dose determined in Cohort D) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours